Onco-cardiology and Cardio-oncology
Prevention of Chemotherapy-induced Cardiotoxicity
Agenda: Friday, November 15, 2013
| Opening 8:00-8:05 a.m. | Edward T.H. Yeh, M.D. |
| Session I 8:05-9:50 a.m. | Cardiotoxicity of Chemotherapy: Four Different Perspectives Moderator: Michael Ewer, M.D., J.D., M.P.H. |
| 8:05-8:25 a.m. | Lymphoma Alma Rodriguez, M.D. |
| 8:25-8:45 a.m. | Breast Cancer Sandra Swain, M.D. |
| 8:45-9:05 a.m. | Sarcoma Robert Benjamin, M.D. |
| 9:05-9:25 a.m. | Pediatric Cancer Steven Lipshultz, M.D. |
| 9:25-10:00 a.m. | Question and Answer Session |
| Break | 10:00-10:15 a.m. |
| Session II 10:15 a.m.- 12:30 p.m. | Primary and Secondary Prevention of Chemotherapy-induced Cardiotoxicity Moderator: Michael Fisch, M.D., M.P.H. |
| 10:15-10:35 a.m. | Primary Prevention Edward T.H. Yeh, M.D. |
| 10:35-10:55 a.m. | Controversy with Dexrazoxane Michael Ewer, M.D., J.D., M.P.H. |
| 10:55-11:15 a.m. | Secondary Prevention Jean-Bernard Durand, M.D. |
| 11:15-11:35 a.m. | Cessation of Therapy and Long-term Monitoring Anecita Fadol, Ph.D., M.S.N. |
| 11:35-12:30 p.m. | Round Table Discussion Moderator: Edward T.H. Yeh, M.D. All Faculty |
| 12:30 p.m. | Adjourn |
Webinar Registration
Registration is required to view the workshop online.
Participating Centers
Key to How Chemotherapy Causes Heart Failure
Key to how chemotherapy drug causes heart failure. See News Release
